Lipid Nanoparticle Delivery of Fas Plasmid Restores Fas Expression to Suppress Melanoma Growth
CTL tumor infiltration
DNA liposome therapy
Fas
FasL DNA hypermethylation
humanized NSG mice
lipid nanoparticle
melanoma PDX
Journal
ACS nano
ISSN: 1936-086X
Titre abrégé: ACS Nano
Pays: United States
ID NLM: 101313589
Informations de publication
Date de publication:
23 08 2022
23 08 2022
Historique:
pubmed:
9
8
2022
medline:
15
11
2022
entrez:
8
8
2022
Statut:
ppublish
Résumé
Fas ligand (FasL), expressed on the surface of activated cytotoxic T lymphocytes (CTLs), is the physiological ligand for the cell surface death receptor, Fas. The Fas-FasL engagement initiates diverse signaling pathways, including the extrinsic cell death signaling pathway, which is one of the effector mechanisms that CTLs use to kill tumor cells. Emerging clinical and experimental data indicate that Fas is essential for the efficacy of CAR-T cell immunotherapy. Furthermore, loss of Fas expression is a hallmark of human melanoma. We hypothesize that restoring Fas expression in tumor cells reverses human melanoma resistance to T cell cytotoxicity. DNA hypermethylation, at the
Identifiants
pubmed: 35939651
doi: 10.1021/acsnano.2c04420
pmc: PMC9721370
mid: NIHMS1854034
doi:
Substances chimiques
fas Receptor
0
Lipid Nanoparticles
0
Fas Ligand Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
12695-12710Subventions
Organisme : CSRD VA
ID : I01 CX001364
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA133085
Pays : United States
Organisme : NCI NIH HHS
ID : F30 CA236436
Pays : United States
Organisme : NCI NIH HHS
ID : F31 CA210612
Pays : United States
Organisme : NIAID NIH HHS
ID : F31 AI120487
Pays : United States
Organisme : BLRD VA
ID : IS1 BX004009
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA227433
Pays : United States
Références
Cancer Immunol Res. 2018 Oct;6(10):1274-1287
pubmed: 30087115
Am J Transl Res. 2014 Jan 15;6(2):114-8
pubmed: 24489990
Blood. 2011 May 19;117(20):5381-90
pubmed: 21450901
Science. 2000 Jun 30;288(5475):2354-7
pubmed: 10875918
Science. 1995 Jun 2;268(5215):1347-9
pubmed: 7539157
J Immunol. 2000 Jul 15;165(2):743-9
pubmed: 10878347
N Engl J Med. 2013 Jul 11;369(2):122-33
pubmed: 23724867
Mol Cancer Res. 2019 Feb;17(2):420-430
pubmed: 30429213
J Exp Med. 1998 Nov 2;188(9):1717-23
pubmed: 9802983
ACS Nano. 2021 Sep 28;15(9):14360-14372
pubmed: 34506129
Science. 1994 Jul 22;265(5171):528-30
pubmed: 7518614
Immunity. 2000 Aug;13(2):265-76
pubmed: 10981969
Melanoma Res. 2002 Jun;12(3):263-70
pubmed: 12140383
Mol Ther. 2017 May 3;25(5):1248-1258
pubmed: 28366766
J Immunol. 2002 Apr 1;168(7):3484-92
pubmed: 11907109
Nat Biotechnol. 1997 Jul;15(7):647-52
pubmed: 9219267
Blood. 2020 Feb 27;135(9):597-609
pubmed: 31830245
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Nature. 2021 Sep;597(7876):318-324
pubmed: 34522017
Nature. 2009 Oct 1;461(7264):659-63
pubmed: 19794494
Nat Genet. 2021 Jan;53(1):86-99
pubmed: 33414553
Cell. 1995 Jun 16;81(6):935-46
pubmed: 7540117
Cancer Immunol Res. 2022 Aug 3;10(8):996-1012
pubmed: 35706413
Cancer Immunol Res. 2019 Mar;7(3):414-427
pubmed: 30610059
Sci Rep. 2022 Feb 28;12(1):3278
pubmed: 35228603
Cell. 2018 Nov 1;175(4):984-997.e24
pubmed: 30388455
Cancer Res. 2007 May 15;67(10):4800-6
pubmed: 17510409
J Exp Med. 1977 Sep 1;146(3):720-34
pubmed: 197192
J Clin Oncol. 2014 Apr 1;32(10):1020-30
pubmed: 24590637
Cancer Res. 1998 Feb 1;58(3):526-34
pubmed: 9458101
Pharmacol Res. 2020 Oct;160:105087
pubmed: 32683036
Blood. 2009 Apr 2;113(14):3276-86
pubmed: 19196867
Mol Cell. 2016 Feb 18;61(4):602-613
pubmed: 26853147
Gene Ther. 1998 Jan;5(1):137-43
pubmed: 9536275
Clin Cancer Res. 2017 Jul 15;23(14):3479-3483
pubmed: 28073844
Nat Commun. 2020 Jan 23;11(1):437
pubmed: 31974367
J Immunother Cancer. 2022 Jan;10(1):
pubmed: 35064010
Nat Immunol. 2000 Dec;1(6):489-95
pubmed: 11101870
Cell Death Differ. 2010 Mar;17(3):551-61
pubmed: 19798106
Cancer Res. 2010 Aug 1;70(15):6313-24
pubmed: 20631069
Sci Rep. 2016 Aug 04;6:30816
pubmed: 27487939
Blood. 2005 Mar 1;105(5):2023-7
pubmed: 15466930
Clin Cancer Res. 2009 Mar 15;15(6):2031-8
pubmed: 19276268
Clin Cancer Res. 2017 Oct 1;23(19):5666-5670
pubmed: 28235882
J Immunother Cancer. 2013 May 29;1:3
pubmed: 24764534
Nature. 2010 May 27;465(7297):492-6
pubmed: 20505730
BMC Genomics. 2020 Jan 2;21(1):2
pubmed: 31898484
Vaccines (Basel). 2013 Jun 25;1(3):225-49
pubmed: 26344110
J Immunol. 2015 Aug 15;195(4):1868-82
pubmed: 26136424
Cancer Discov. 2011 Dec;1(7):598-607
pubmed: 22586682
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Lancet. 1996 Sep 14;348(9029):719-23
pubmed: 8806292
Cancer Cell. 2002 Aug;2(2):139-48
pubmed: 12204534
Nat Immunol. 2022 May;23(5):660-670
pubmed: 35241833
BMC Cancer. 2021 Nov 13;21(1):1222
pubmed: 34774008
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Gut. 2005 May;54(5):661-5
pubmed: 15831912
Science. 2022 May 13;376(6594):eabl5197
pubmed: 35549406
Nat Rev Immunol. 2018 Aug;18(8):527-535
pubmed: 29662120
Cancer Immunol Res. 2019 Aug;7(8):1267-1279
pubmed: 31186248
Cancer Discov. 2020 Apr;10(4):552-567
pubmed: 32001516
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32217765
J Immunol. 2012 Dec 1;189(11):5097-100
pubmed: 23169861
Int J Cancer. 1994 May 1;57(3):371-7
pubmed: 8168998
Nature. 1992 Mar 26;356(6367):314-7
pubmed: 1372394
Clin Cancer Res. 2017 Oct 1;23(19):5661-5665
pubmed: 28179454
Cancers (Basel). 2022 Jan 12;14(2):
pubmed: 35053524
Cancer Discov. 2021 Mar;11(3):599-613
pubmed: 33334730
Nat Commun. 2016 Dec 23;7:13895
pubmed: 28008916
Cancer Immunol Res. 2018 Feb;6(2):163-177
pubmed: 29339375
Nature. 2009 Aug 20;460(7258):1035-9
pubmed: 19626005
Cell Death Differ. 2003 Feb;10(2):211-7
pubmed: 12700649
Nat Med. 2014 Mar;20(3):283-90
pubmed: 24487434
PLoS One. 2012;7(4):e34833
pubmed: 22558101
Cell. 2016 Oct 6;167(2):397-404.e9
pubmed: 27667683
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Clin Cancer Res. 2008 Sep 1;14(17):5385-99
pubmed: 18765530
J Exp Med. 2017 Apr 3;214(4):895-904
pubmed: 28302645